abstracts

12/15/2021

P032 Clinical Usefulness of Double Balloon Enteroscopy in Patients With Established or Suspected Small Bowel Crohn’s Disease

BACKGROUND: The diagnosis of isolated small bowel Crohn’s disease (CD) can be challenging. Symptoms are non-specific and both imaging and capsule endoscopy (CE) may be mislead...

12/15/2021

P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

BACKGROUND: Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD). Patients with concomitant PSC-IBD are at higher risk for IBD-related comp...

12/15/2021

P033 Moving the Needle on Speaker Diversity at AIBD

BACKGROUND: Diversity of invited speakers at academic conferences is a topic of increased focus in recent years. While there have been efforts to improve speaker diversity, an...

12/15/2021

P023 Parental Distress in Pediatric Inflammatory Bowel Disease

BACKGROUND: Prior studies have shown that parents of children with inflammatory bowel diseases (IBD) have significantly more symptoms of depression and anxiety...

12/15/2021

P034 State of Health Maintenance Among IBD Patients at a Tertiary Care Center in Abu Dhabi, United Arab Emirates

BACKGROUND: Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) affecting 6.8 million persons globally. Treatment of IBD focuses largely on ...

12/15/2021

P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study

BACKGROUND: Fecal incontinence (FI) affects up to 1 in 4 patients with inflammatory bowel disease (IBD) and is associated with inflammation, surgeries, and altered rectal sens...

12/15/2021

P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study

BACKGROUND: True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with on...

12/15/2021

P025 The Impact of Non-Remission on Costs and Resource Use In Patients With Crohn’s Disease: Targeted Literature Review

BACKGROUND: The incidence of Crohn’s disease (CD) has been rising globally. Patients with CD are at an increased risk of mortality compared to general population. The goal of ...

12/15/2021

P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial

BACKGROUND: Ozanimod is an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P 1 and S1P ...

12/15/2021

abstracts

Follow Us on Twitter!

Specialties

Events

Year Round Education

HMP Global Products